CLAIMS

What is claimed is:

1. A compound having the structure of Formula I



Formula I

,

or a salt thereof,

wherein R^A is tetrazolyl, -C(=O)NH_2, -C(=O)NHR^B, -CONHCN, -C(=O)$NHSO_2R^B$ or -C(=O)$NHCH_2CH_2SO_3H$;

R_B, which is a partial structure of R_A, is C_1-C_4 saturated alkyl

L_1 is  ;

A^1 is N or CH;

Ring A has the structure of:



, ;

R^C ,

which is a partial structure of Ring A, is –Cl;

R^D , which is a partial structure of Ring A, is –N(R^F)-C(=O)XCH(R^G)-CY (Formula II), in which X is O and CY is unsubstituted phenyl or phenyl substituted with one R^H:



(II) ;

R^E of Formula II is -H or C_1-C_4 saturated alkyl and R^G of Formula II is -H or C_1-C_4 saturated alkyl;

R^H of Formula I and II is independently –H, halogen or C_1-C_4 saturated alkyl.

2. The compound according to claim 1, wherein:

R^A of Formula I is tetrazolyl (), –C(=O)NH_2, -CONHCN or –C(=O)$NHSO_2R^B$;

L^1 is ;

in the ring , which is a partial structure of Formula I, R^H is –H, a halogen, or –CH_3;

in the ring ,which is a partial structure of Formula I, A^1 is CH or N and R^H is –H;

Ring A, which is a partial structure of Formula I, has the structure of ;

R^C , which is a partial structure of Ring A,, is –Cl;

R^F of Formula II is –H;

R^G of Formula II is –CH_3 in an R configuration; and

in the CY ring , which is a partial structure of Formula II, R^H is –H or a halogen.

3. The compound according to claim 2, wherein:

R^A of Formula I is -C(=O)$NHSO_2R^B$, where R^B is –CH3; and

L^1 is ;

R^C , which is a partial structure of Ring A that is a partial structure of Formula I, is -Cl; and

in the ring 

, which is a partial structure of Formula I, A^1 is CH and R^H is -H.

4. The compound according to claim 3, wherein the compound is selected from the group consisting of (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(2'-fluoro-4'-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-chloro-1-(4'-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, and salts thereof.

5. The compound according to claim 2, wherein:

R^A of Formula I is tetrazolyl (

);

L^1 is  ; and

R^C , which is a partial structure of Ring A that is a partial structure of Formula I, is -Cl; and

in the ring 

, which is a partial structure of Formula I , A^1 is CH and R^H is –H.

6. The compound according to Claim 5, wherein the compound is selected from the group consisting of (R)-1-phenylethyl (1-(4'-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-chloro-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4'-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate and salts thereof.

7. The compound according to claim 2, wherein:

R^A of Formula I is -CONHCN

L^1 is  ; and

R^C , which is a partial structure of Ring A that is a partial structure of Formula I, is -Cl; and

in the ring 

, which is a partial structure of Formula I, A^1 is CH and R^H is –H.

8. The compound according to claim 7 wherein the compound is selected from the group consisting of (R)-1-phenylethyl (4-chloro-1-(4'-(1-(cyanocarbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(4'-(1-(cyanocarbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate and salts thereof.

9. The compound according to claim 2 wherein the compound is (R)-1-phenylethyl (4-chloro-1-(4'-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate or a salt thereof.

10. The compound according to claim 1, wherein the carbon atom covalently attached to R^G is in an R configuration.

11. The compound according to claim 1, wherein the carbon atom covalently attached to R^G is in an S configuration.

12. The compound according to claim 10, wherein the compound is selected from the group consisting of (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(2'-fluoro-4'-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-chloro-1-(4'-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (1-(4'-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4'-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate, 3-[(R)-1-Phenylethoxycarbonylamino]-4-chloro-2-{4'-[1-(cyanoamino)carbonylcyclopropyl]-4-biphenylyl}-2H-pyrazole, 3-[(R)-1-(o-

Chlorophenyl)ethoxycarbonylamino]-4-chloro-2-{4'-[1-(cyanoamino)carbonyl-cyclopropyl]-4-biphenylyl}-2H-pyrazole and salts thereof.

13. A pharmaceutical composition comprising:
a compound according to claim 1; and
one or more pharmaceutically acceptable excipients.

14. Use of a compound for the manufacture of a medicament for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof, wherein the compound is according to any one of claims 1-12.

15. The use according to claim 14, wherein the lysophosphatidic acid-dependent disease or condition is nonalcoholic steatohepatitis (NASH).

16.The use according to claim 15, wherein the lysophosphatidic acid-dependent disease or condition is diabetic nephropathy.

17. The use according to claim, 15, wherein the lysophosphatidic acid-dependent disease or condition is fibrosis of an organ.

18. The use according to claim 17, wherein the organ is liver.